Navigation Links
Stem Cell Decision Opens New Doors, May Spur More Research

Some avenues of scientific inquiry remain unfunded, however,,

WEDNESDAY, July 15 (HealthDay News) -- The U.S. National Institutes of Health (NIH) announced last week their new guidelines for stem cell research funding, including allowing some previously ineligible stem cell lines to receive federal grants, provided they were obtained in an ethical manner.

But, will these new rules really expand the field of stem cell research and help find new treatments, possibly even cures, for devastating diseases?

"I think that everybody felt that when President Obama issued the executive order [on stem cell research in March], the most important thing was to expand the ability to investigate more lines," said Story Landis, head of the NIH stem cell task force, and director of the National Institute of Neurological Disorders and Stroke. And, estimates place the number of potential new stem cell lines at around 700.

Stem cells -- embryonic and adult -- offer promise in the treatment of numerous diseases, such as macular degeneration, spinal cord injury, Parkinson's disease, type 1 diabetes, Lou Gehrig's disease and heart disease, among others.

Alan Lewis, president and CEO of the Juvenile Diabetes Research Foundation, said, "At JDRF, we've long been supporters of encouraging stem cell research. Opening up the opportunities to get grant funding is really going to be critical to great progress in diabetes and other diseases."

One good example of how these new guidelines may help researchers is the inclusion of what's known as pre-implantation genetic diagnosis, Landis said.

"The 21 lines that were eligible under President Bush only included embryos from people who were genetically normal," he said. "But since then, a number of investigators have generated lines from pre-implantation genetic diagnosis (PGD) that were determined to carry a gene defect, which is important for studying diseases like cystic fibrosis. In PGD, a couple prepares for in-vitro fertilization, and it's possible to take one cell from a really early embryo to let you know which embryos are fine, and which carries two copies, in this case of a cystic fibrosis gene. While it's been possible to make lines from those embryos prior to this decision, they weren't eligible for federal money before, but they are now."

Added Meri Firpo, an assistant professor at The Stem Cell Institute at the University of Minnesota: "Now everyone can work with these PGD lines, and this will bring a lot more people into doing research with these cells, which may move progress faster."

Under the Bush administration rules, because so few stem cell lines were available for federal research funding, separate laboratories had to be set up, as well as separate accounting systems to ensure that equipment costs and salaries for research paid for by federal money weren't used to conduct research on unapproved stem cell lines. Not surprisingly, some researchers decided to forgo stem cell research because of these restrictions.

However, the actual creation of stem cell lines is still something that can't be done with federal funding, Firpo said. Once the lines have been created -- if they're deemed to have been created in an ethical manner and they pass NIH review -- then the lines can be used for federal research.

Additionally, researchers can't use federal money for research from embryos created solely for research.

"The federal government is opening the door, but the door isn't wide open," said Susan Solomon, chief executive officer of the New York Stem Cell Foundation, a private organization that funds stem cell research.

Whether the NIH ever revisits its decision on controversial techniques for creating stem cells, Solomon said there will always likely be a need for private and state funding for stem cell research because obtaining a federal grant is a slow process.

"We have urgent patient needs right now. Every day that goes by, the clock is ticking for people with chronic illness and the federal government isn't designed to respond to that kind of urgency," she said.

Kevin Eggan, chief scientific officer for the New York Stem Cell Foundation, and an assistant professor of stem cell and regenerative biology at Harvard University, agreed with Solomon, adding, "Federal money isn't responsive to immediate needs and short timelines. Sometimes, with small, strategic infusions of money, there can be a massively changing shift in research."

More information

For a primer on stem cells, visit the U.S. National Institutes of Health.

SOURCES: Story Landis, Ph.D., director, National Institute of Neurological Diseases and Stroke, and head, NIH Stem Cell Task Force, Bethesda, Md.; Alan J. Lewis, Ph.D., president and CEO, Juvenile Diabetes Research Foundation International, New York City; Susan Solomon, chief executive officer, New York Stem Cell Foundation, New York City; Kevin Eggan, Ph.D., assistant professor, stem cell and regenerative biology, Harvard University, Boston, and chief scientific officer, New York Stem Cell Foundation, New York City; Meri Firpo, Ph.D., assistant professor, The Stem Cell Institute, University of Minnesota, Minneapolis; NIH Guidelines for Human Stem Cell Research, July 6, 2009

Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Gerresheimer to be Included in the SDAX Early Decision on Inclusion in the MDAX on September 5, 2007
2. Microarray provides 3 genomic guides to breast cancer treatment decisions
3. Spectranetics to Appeal Decision in Patent Litigation
4. Canadas government funds $1.6M in modern geography to support public health decisions
5. Parents participation in medical decisions linked to self-efficacy
6. Decision-making by residents on-call has miniscule negative impact on patient care
7. Political decisions harming cancer treatment in Europe
8. UniCare Introduces Consumer-Driven Health Products to Give Consumers a Bigger Role in Health Care Decisions
9. Equipping your Sales Force to Influence Hospital Formulary Decision-Makers
10. Newton-Wellesley Hospital First in Massachusetts to Implement Isabel Diagnosis Decision Support System
11. Autism Speaks Applauds Supreme Court Decision Upholding Families Right to Challenge IEPs Without First Trying Out School District Proposed Placement
Post Your Comments:
(Date:11/24/2015)... VA (PRWEB) , ... November 24, 2015 , ... ... people across the United States to support their local poison centers through donations ... designated as #GivingTuesday: calls it “a day that inspires people to collaborate ...
(Date:11/24/2015)... ... 24, 2015 , ... Serenity Point Rehabilitation, a holistic treatment center for substance ... some of the staff members at their recovery center. The videos highlight some of ... some of the things that make their recovery program so unique. , “Making the ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Aided by seed ... announced an innovative study designed to yield insights into how to detect and treat ... biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic material that is ...
(Date:11/24/2015)... ... 2015 , ... Abington Hospital – Jefferson Health is pleased ... Surgery Facility for treating individuals living with morbid or extreme obesity. , Aetna ... its members to help them make informed decisions about their healthcare needs. In ...
(Date:11/24/2015)... ... 2015 , ... Dr. Rodney E. Willey , has answered a new calling – to ... Disorders, provides treatment for snoring and sleep apnea through oral appliance therapy. ... Sleep Disorders in the US, one of four in the Illinois area. , Dr. ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 24, 2015 F1000Workspace - a ... since it was launched just six months ago. --> ... authoring platform for scientists - since it was launched just ... been loaded on to F1000Workspace - a research ... it was launched just six months ago. ...
(Date:11/24/2015)... Nov. 24, 2015 iRhythm Technologies, Inc. , a ... today announced that it will participate in the 27th Annual Piper ... New York, NY . Kevin King , ... December 1, 2015 at 8:50am ET. --> ... . --> . --> iRhythm ...
(Date:11/24/2015)... uptake of recently approved and pipeline premium products for Type 1 Diabetes ... says GBI Research . --> The ... Mellitus (T1DM), will be a key driver of market growth to 2021, ... The uptake of recently approved and pipeline premium products for Type 1 ... 2021, says GBI Research . Type ...
Breaking Medicine Technology: